All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Ameluz, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 3 for the same window.
Recent coverage · Armanino Foods of Distinction, Inc.
1story
avg impact
0%positive
0%negative
100% neutral
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Armanino Foods of Distinction, Inc.
All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Ameluz, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 3 for the same window. Their average consequence score of 5 runs below the beat's 5.9 for that window. We currently track 1 Healthcare story that mention Armanino Foods of Distinction, Inc., all published on March 19, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Armanino Foods of Distinction, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Biofrontera Inc. (Nasdaq: BFRI) has reported record-breaking financial results for the fourth quarter and full year 2025, signaling a major milestone in the commercial adoption of its photodynamic therapy (PDT) solutions. The company is leveraging increased market penetration of its flagship product, Ameluz, and its proprietary BF-RhodoLED lamps across U.S. dermatology practices.
Armanino Foods of Distinction, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.
